Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Argus analyst Kristina Ruggeri raised the firm’s price target on Cardinal Health (CAH) to $148 from $145 and keeps a Buy rating on the shares.

Cardinal Health Inc. closed 5.65% below its 52-week high of $132.84, which the company achieved on January 30th.